Predict your next investment

FINANCIAL | Investment Banking
feltl.com

See what CB Insights has to offer

Founded Year

2002

About Feltl and Company

Feltl and Company is a full-service stock brokerage firm, a registered investment advisor, and an investment banking firm with special expertise in following and financing emerging growth companies, primarily located in the Upper Midwest.

Feltl and Company Headquarter Location

10900 Wayzata Boulevard Suite 200

Hopkins, Minnesota, 55305,

United States

Latest Feltl and Company News

Cancer Genetics Prices Public Offering of Securities

Nov 6, 2015

Cancer Genetics Prices Public Offering of Securities 11/6/15 RUTHERFORD, N.J., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX ) today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $4.00 per share, with five year warrants to purchase 3,000,000 shares of common stock at an exercise price of $5.00 per share. The gross proceeds to Cancer Genetics from this offering are expected to be $12.0 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by Cancer Genetics. The underwriters have been granted a 45-day option to purchase up to an aggregate of 450,000 additional shares of common stock and/or 450,000 additional warrants. The offering is expected to close on or about November 12, 2015, subject to customary closing conditions. Joseph Gunnar & Co., LLC and Feltl and Company, Inc. are acting as the joint book-running managers for the offering. Axiom Capital Management, Inc. is acting as co-manager for the offering. About Cancer Genetics, Inc. Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For more information, please visit or follow us:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.